Patients with myotonic dystrophy (MD) have an increased risk of malignancy including uveal melanoma. This case series further explores the association between these 2 diseases.
M yotonic dystrophy (MD) is an autosomal dominant muscular dystrophy characterized by progressive muscle weakness, myotonia, cardiac conduction deficits, and early onset cataracts. 1 It is one of the most common genetic muscle disorders affecting patients of European descent (prevalence, approximately 1 in 8000) and there are 2 genetic subtypes. 1 Myotonic dystrophy type 1 (MD1; Steinert disease) is caused by a CTG trinucleotide repeated expansion in the DMPK gene on chromosome 19 (OMIM 160900). 1 Myotonic dystrophy type 2 (MD2; Ricker syndrome) is caused by a CCTG tetranucleotide repeated expansion in the CNBP (ZNF9) gene on chromosome 3 (OMIM 602668). 1 Several studies have confirmed that patients with MD have an increased risk of malignancy including choroidal melanoma, non-Hodgkin lymphoma, and cancers of the brain, colon, endometrium, ovary, testicle, and thyroid. [2] [3] [4] [5] [6] In patients with MD, malignancies account for 10% of all deaths, and the absolute risk of cancer mortality increases from 2% at age 50 years to 6% at age 70 years. 6 To our knowledge, there is only 1 prior report describing 3 patients with uveal melanoma associated with MD1. 7 We describe 6 additional cases of MD-associated uveal melanoma.
Methods
This study is in compliance with the Health Insurance Portability and Accountability Act and received institutional review board approval from Wills Eye Hospital. Records from 3 ocular oncology practices (Wills Eye Hospital, Philadelphia, Pennsylvania; Mayo Clinic, Rochester, Minnesota; and Moorfields Eye Hospital, London, England) were retrospectively reviewed for concurrent MD and uveal melanoma. All patients agreed to participate in research per each institution's unique protocol. While consent for research was obtained, specific consent for this study was waived because some patients were deceased or lost to followup at the time of retrospective review.
Results
Six patients with uveal melanoma were found to have underlying MD (Table) . Two cases were included in a prior large series, 3 but none of the included cases have been previously reported in detail.
Case 1
A young white woman with MD1 diagnosed when she was a teenager (100 trinucleotide repeats in DMPK) had an intraocular mass. Review of systems was remarkable for foot drop and marked oxygen desaturation following general anesthesia. Family history was positive for cutaneous melanoma, Merkel cell carcinoma, and MD. Ophthalmic examination showed pseudophakia in both eyes and a macular pigmented choroidal melanoma in the right eye with overlying orange pigment ( Figure 1A ), measuring 6 mm in largest basal diameter. Fundus autofluorescence revealed spokelike lipofuscin overlying the lesion ( Figure 1B) . B-scan ultrasonography depicted an echolucent choroidal mass, measuring 2.5 mm in thickness ( Figure 1C ). The melanoma was treated with iodine 125 plaque radiotherapy with transpupillary thermotherapy consolidation. On 6-month follow-up, the tumor demonstrated regression and there was no evidence of metastases.
Case 2
A middle-aged white man with no history of MD displayed aged facial features, pasty white skin tone, and transient atrial fibrillation. Slitlamp biomicroscopy revealed polychromatic (Christmas tree) cataract in both eyes. Funduscopy of the right eye revealed a pigmented choroidal melanoma temporal to the macula (eFigure, A in the Supplement) with overlying lipofuscin (eFigure, B in the Supplement), measuring 7 mm in largest basal diameter and 1.8 mm in thickness with acoustic hollowness on ultrasonography (eFigure, C in the Supplement).
Owing to clinical suspicion, genetic testing was performed and revealed MD1 (644 trinucleotide repeats in DMPK). The patient was treated with iodine 125 plaque radiotherapy and transpupillary thermotherapy. At 87 months follow-up, tumor regression was documented, with no evidence of metastases.
Case 3
A middle-aged white man with adult-onset MD1 was referred for evaluation of a pigmented choroidal mass in the right eye. There was no personal or family history of cancer. Examination revealed Christmas tree cataract in both eyes. Funduscopy of the right eye showed a pigmented choroidal melanoma with overlying orange pigment and subretinal fluid. Treatment with ruthenium-106 plaque radiotherapy resulted in tumor regression, with no evidence of metastases at 41 months follow-up. The patient subsequently died following myocardial infarction.
Case 4
A middle-aged white woman (a relative of case 3) with adultonset MD1 had a choroidal mass in the left eye. She had no personal history of cancer, but her relative had choroidal melanoma. Examination revealed pseudophakia in both eyes and a pigmented choroidal melanoma in the left eye with orange pigment and thickness 1.5 mm. The patient was treated with
Key Points
Question Is uveal melanoma associated with myotonic dystrophy?
Findings In this case series, 6 patients were found to have myotonic dystrophy-associated uveal melanoma, including a case of myotonic dystrophy-associated iris melanoma and myotonic dystrophy-associated uveal melanoma in relatives. With variable follow-up of 6, 6, 41, 42, and 87 months (5 patients), findings included melanoma regression (4 of 5 tumors), melanoma recurrence (1 of 5 tumors), and no metastatic disease (5 of 5 patients); 1 patient declined treatment or follow-up.
Meaning These findings suggest an association of myotonic dystrophy and uveal melanoma; patients with myotonic dystrophy may benefit from periodic ophthalmic examination. 
Case 5
A middle-aged white man with history of MD diagnosed in young adulthood and Christmas tree cataract in both eyes removed prior to referral was seen for evaluation of an iris lesion in the right eye. Family history was positive for MD and breast cancer. Examination disclosed belpharoptosis ( Figure 2A ) and pseudophakia in both eyes. Anterior segment examination of the right eye demonstrated a pigmented, multinodular, diffuse, ring-shaped iris melanoma ( Figure 2B ) with invasion into the trabecular meshwork ( Figure 2C ), measuring 3.0 mm in thickness. The patient was treated with epicorneal iodine 125 plaque radiotherapy, and the tumor regressed with no metastatic disease at 42 months' follow-up.
Case 6
A middle-aged Middle Eastern man with adult-onset MD was referred for evaluation of a pigmented choroidal lesion in the right eye. Family history was significant for MD, lymphoma, and lung cancer and a personal history of basal cell carcinoma. Examination showed nuclear sclerotic cataract without polychromasia in both eyes. Funduscopy in the right eye revealed a choroidal melanoma with overlying orange pigment, measuring 14 mm in basal diameter and 3.7 mm in thickness. The patient was offered iodine 125 plaque radiotherapy but declined treatment or further follow-up (alive at 2 months by telephone). 
Discussion
To our knowledge, this is the largest series of MD-associated uveal melanoma to date. We include the first reported case of MD-associated iris melanoma and MD-associated uveal melanoma in relatives. There were 6 patients (4 of 6 [67%] were men) diagnosed with MD in young adulthood (n = 2; 33%) or older (n = 4; 67%), each with features of MD, including muscle weakness (n = 5; 83%), myotonia (n = 4; 67%), polychromatic cataract (n = 4; 67%), complications with general anesthesia (n = 4; 67%), myalgia (n = 3; 50%), cardiac arrhythmia (n = 2; 33%), and frontal baldness (n = 2; 33% 
Limitations
Limitations of our study include lack of genetic testing in 2 of 6 patients, preventing us from definitively stating that uveal melanoma has been exclusively associated with MD1. Additionally, while neither our series nor prior reports have associated metastatic uveal melanoma with MD, 7 longer follow-up is necessary to better evaluate the risk of tumor spread in these patients.
Conclusions
Given the association between uveal melanoma and MD, consideration should be given to ophthalmic examinations with careful attention to any iris, ciliary body, or choroidal lesions. Future studies may further delineate the pathogenesis of uveal melanoma in patients with MD and define best cancer screening practices.
